Tonghua Golden-Horse Pharmaceutical Industry (000766) Fundamentals 2026 — P/E 485.4x, Revenue Analysis | SniperIQ
Tonghua Golden-Horse Pharmaceutical Industry (000766) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥15.4B, trading at ¥15.92 on the SHZ. This SniperIQ fundamentals page covers Tonghua Golden-Horse Pharmaceutical Industry's valuation (P/E 485.4x, P/B 6.7x), profitability (net margin 2.7%), revenue (¥1.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Tonghua Golden-Horse Pharmaceutical Industry's market cap?
Tonghua Golden-Horse Pharmaceutical Industry (000766) has a market capitalization of approximately ¥15.4B, trading at ¥15.92 on the SHZ. Market cap moves with the live share price.
What is Tonghua Golden-Horse Pharmaceutical Industry's P/E ratio?
Tonghua Golden-Horse Pharmaceutical Industry's trailing twelve-month P/E ratio is 485.4x, with a price-to-book (P/B) of 6.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Tonghua Golden-Horse Pharmaceutical Industry?
Tonghua Golden-Horse Pharmaceutical Industry runs a net profit margin of 2.7%, a gross margin of 72.9%, and an operating margin of 4.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Tonghua Golden-Horse Pharmaceutical Industry generate?
Tonghua Golden-Horse Pharmaceutical Industry reported revenue of ¥1.2B for fiscal year 2025, with net income of ¥34M and earnings per share (EPS) of 0.04. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Tonghua Golden-Horse Pharmaceutical Industry pay a dividend?
Tonghua Golden-Horse Pharmaceutical Industry does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Tonghua Golden-Horse Pharmaceutical Industry financially healthy?
Tonghua Golden-Horse Pharmaceutical Industry carries a debt-to-equity ratio of 0.87x and a current ratio of 1.90x, with a market beta of 0.53. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Tonghua Golden-Horse Pharmaceutical Industry a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Tonghua Golden-Horse Pharmaceutical Industry (000766) the key facts are: market cap ¥15.4B, P/E 485.4x, revenue ¥1.2B, 52-week range 14.94-30.2. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Tonghua Golden-Horse Pharmaceutical Industry's full fundamentals live
Get Tonghua Golden-Horse Pharmaceutical Industry's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.